Predictors and ocular outcomes of rescue treatment in preterm infants with treated retinopathy of prematurity—a retrospective study
暂无分享,去创建一个
H. Balasubramanian | L. Srinivasan | N. Kabra | Prachi Agashe | Ashish Doshi | Mythily Sindhur | A. Malpani
[1] N. Marlow,et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial , 2019, The Lancet.
[2] C. Gilbert,et al. Retinopathy of prematurity - A world update. , 2019, Seminars in perinatology.
[3] G. Natarajan,et al. Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment , 2019, Pediatrics.
[4] A. Razak,et al. Association of small for gestational age with retinopathy of prematurity: a systematic review and meta-analysis , 2019, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[5] S. Honavar. Do we need India-specific retinopathy of prematurity screening guidelines? , 2019, Indian journal of ophthalmology.
[6] D. Moshfeghi,et al. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity. , 2019, American journal of ophthalmology.
[7] G. Abbott. Detachment , 2018, Thucydides.
[8] A. Mathur,et al. Early Red Cell Transfusion is Associated with Development of Severe Retinopathy of Prematurity , 2018, Journal of Perinatology.
[9] Parijat Chandra,et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. , 2018, The Cochrane database of systematic reviews.
[10] Steven P. Miller,et al. Severe retinopathy of prematurity predicts delayed white matter maturation and poorer neurodevelopment , 2017, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[11] Guoming Zhang,et al. COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY , 2017, Retina.
[12] L. Lehtonen,et al. International variations and trends in the treatment for retinopathy of prematurity , 2017, British Journal of Ophthalmology.
[13] C. Bunce,et al. Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk , 2017, BMJ Open.
[14] K. Falavarjani,et al. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review. , 2016, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
[15] A. Hellström,et al. Ophthalmologic Outcome of Extremely Preterm Infants at 6.5 Years of Age: Extremely Preterm Infants in Sweden Study (EXPRESS). , 2016, JAMA ophthalmology.
[16] F. Lefebvre,et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity , 2016, Pediatrics.
[17] Rachelle G. Anzures,et al. Practice Patterns in Retinopathy of Prematurity Treatment for Disease Milder Than Recommended by Guidelines. , 2016, American journal of ophthalmology.
[18] V. Bhat,et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. , 2016, The Cochrane database of systematic reviews.
[19] Wei-Chi Wu,et al. Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment , 2016, PloS one.
[20] A. Hutchinson,et al. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. , 2015, Ophthalmology.
[21] A. Chuang,et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. , 2014, JAMA ophthalmology.
[22] Y. Hwang,et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes , 2014, Eye.
[23] C. Bunce,et al. Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. , 2013, The Journal of pediatrics.
[24] Alice Z Chuang,et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.
[25] R. Hardy,et al. Astigmatism in the Early Treatment for Retinopathy Of Prematurity Study: findings to 3 years of age. , 2009, Ophthalmology.
[26] R. Hardy,et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. , 2008, Ophthalmology.
[27] G. Holmström,et al. Long-term follow-up of visual functions in prematurely born children--a prospective population-based study up to 10 years of age. , 2008, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
[28] M. Trese,et al. Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. , 2008, American journal of ophthalmology.
[29] S. Schwartz,et al. ASSOCIATION OF SYSTEMIC RISK FACTORS WITH THE PROGRESSION OF LASER-TREATED RETINOPATHY OF PREMATURITY TO RETINAL DETACHMENT , 2008, Retina.
[30] Anna L. Ells,et al. The International Classification of Retinopathy of Prematurity revisited. , 2005, Archives of ophthalmology.
[31] W. Tasman,et al. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.
[32] A. Fielder,et al. Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.
[33] C. Gilbert,et al. Childhood blindness in the context of VISION 2020--the right to sight. , 2001, Bulletin of the World Health Organization.
[34] J. M. Miller,et al. Spectacle prescribing recommendations of AAPOS members. , 1998, Journal of pediatric ophthalmology and strabismus.
[35] G. Quinn,et al. Myopia of prematurity: nature, nurture, or disease? , 1997, The British journal of ophthalmology.